What is Tarsus Pharmaceuticals, Inc.'s 2031?

Tarsus Pharmaceuticals, Inc. (TARS) reported 2031 of $961K in Q4 2025.

What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s 2031?

Over 2 years (2023 to 2025), Tarsus Pharmaceuticals, Inc.'s 2031 has grown at a 55.0% compound annual growth rate (CAGR), from $400K to $961K.

Tarsus Pharmaceuticals, Inc. TARS 2031

2031 at other companies

Bausch + LombBLCO

——

Other financials

Income statement

See full

Revenue$162.1M+107%

Gross profit$152.7M+109%

Operating income-$6.1M+76.7%

Net income-$7.0M+72.3%

EPS (diluted)-$0.16+75.0%

Balance sheet

See full

Cash & equivalents$104.2M-41.6%

Total debt$88.7M+22.5%

Total equity$349.0M+1.9%

Total assets$581.1M+16.1%

Cash flow

See full

Operating cash flow-$24.7M-19.4%

CapEx$5.8M+886%

Free cash flow-$30.5M-43.4%

Valuation

See full

Market cap$2.85B+41.1%

Enterprise value$2.83B+47.8%

P/S5.3×-3.3×

Profitability

See full

Gross margin42.7%—

Operating margin-9.5%-4.2pp

Net margin-9%-4.0pp

FCF margin-28%-12.6pp

Returns & leverage

See full

Return on equity-14%-5.2pp

Debt / equity0.3×0.0×

Current ratio3.7×-1.8×

Where this comes from

Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive.

The official record: Tarsus Pharmaceuticals, Inc.’s 10-K, filed February 23, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tarsus Pharmaceuticals, Inc.'s 2031.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Tarsus Pharmaceuticals, Inc.'s 2031?: Tarsus Pharmaceuticals, Inc. (TARS) reported 2031 of $961K in Q4 2025.
What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s 2031?: Over 2 years (2023 to 2025), Tarsus Pharmaceuticals, Inc.'s 2031 has grown at a 55.0% compound annual growth rate (CAGR), from $400K to $961K.